Aisling plots a new $500M biotech fund

Aisling Capital is raising a new fund, looking to gather up to $500 million for a new wave of life science investments, according to a report in Fortune. Aisling's last fund rang in at $650 million, but the scoop from Dan Primack says this new effort is aimed at rounding up $400 million with a hard cap at $500 million. Aisling's recent biotech investments include a stake in an $80 million round for Allergen Research and a $53 million raise for Watertown, MA-based Syros. Story

Suggested Articles

In this week's EuroBiotech Report, GSK, Immatics strike cell therapy deal, Vifor buys priority review voucher and PharmaMar gets PDUFA date.

In our EuroBiotech roundup this week, U.K. creates life science zones, Genmab to ramp up R&D spending and Pfizer backs cancer biotech. 

Spruce Biosciences raised $88 million from the likes of Abingworth and Omega Funds to take the drug to the next level: a late-stage study in adults.